| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Grail Plants a Seed in RTP, Pledges $100M Investment in New Site | Frank Vinluan | 06/02/20 | Raleigh Durham |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19) | Frank Vinluan | 04/22/20 | National |
| New COVID-19 Special Reports Explore Clinical Research During the Pandemic | Editors | 04/21/20 | Boston |
| Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More | Sarah de Crescenzo | 04/17/20 | National |
| GSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year | Frank Vinluan | 04/14/20 | National |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Pfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month | Frank Vinluan | 04/09/20 | National |
| Roche Pays $190M to Start RNA Drug Alliance With Arrakis Therapeutics | Frank Vinluan | 04/08/20 | Boston |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
